The Longevity Clinic Business Model: A Unit-Economics Teardown

A longevity clinic runs on recurring revenue, not one-off sales. It charges a membership or program fee for provider oversight, lab work, and monitoring, then earns subscription revenue on compounded therapies a licensed provider approves for each patient — peptides, NAD+, bio-identical hormones, low-dose naltrexone, and metabolic panels. Spreading revenue across many categories is what keeps the model durable.

That sentence hides a lot of operating reality. Below is the honest teardown: where the money comes from, what the margins actually look like after costs, why retention decides everything, and where the compliance line sits. This is written from the operator's chair, not the brochure.

What is the business model of a longevity clinic?

The longevity clinic model is two recurring revenue lines stacked on top of provider oversight. Line one is a membership or program fee that pays for clinical supervision, labs, and monitoring. Line two is subscription revenue from compounded therapies a licensed provider approves. Breadth across categories protects the whole thing from any single regulatory change.

What makes this a clinic and not a storefront is the oversight. Every therapy in the catalog is a prescription product. A licensed provider reviews the patient, approves the order, and stays in the loop on refills and dose changes. That is not optional friction to route around — it is the load-bearing wall of the model and the reason the revenue is defensible. If you can strip the provider out and sell the same thing as a consumer good, you were never running a clinic.

What therapies do longevity clinics actually sell?

Most longevity catalogs cluster into a handful of categories: peptides, NAD+ (oral, sublingual, or injectable), bio-identical hormone replacement therapy (BHRT), low-dose naltrexone (LDN), and metabolic or performance panels. The important operator fact is that the majority of these are compounded, off-label preparations rather than FDA-approved products for anti-aging or healthspan use.

Be honest about the science. These therapies are prescribed at a provider's clinical discretion, and the evidence base varies widely by category and by use. This post is not going to tell you NAD+ reverses aging or that a given peptide does what a marketing page claims — because the FDA's compounding guidance and its category lists have moved on some of these, and the smart operator markets the service and the supervision, not efficacy claims. What you are selling is provider-supervised access and a program, not a cure.

Mechanically, almost all of this lives on the non-controlled 503A side, which is the safe default for a clinic getting started. Hormones are where controlled-substance rules can enter — testosterone is a Schedule III controlled substance under the Controlled Substances Act, so any TRT line depends on the current DEA telemedicine flexibility window and careful DEA-aware prescribing. If you plan to offer TRT, treat it as a separate compliance track, not a catalog line item.

How does a longevity clinic make money?

Revenue comes from combining a predictable membership base with variable subscription refills. The membership smooths cash flow and pays for the clinical layer; the therapy subscriptions carry the margin. The best operators design the two so a patient's first month covers onboarding and each subsequent month is high-contribution recurring revenue.

Here is a representative revenue-stream breakdown. The figures below are illustrative structure, not benchmarks — your actual mix depends on catalog, pricing, and payor model.

Revenue stream	What it is	Typical margin profile	Role in the model
Membership / program fee	Monthly or quarterly fee for provider oversight, labs, monitoring	High margin, low COGS after provider time	Smooths cash flow, funds the clinical layer
Compounded therapy subscription	Recurring refills of peptides, BHRT, LDN, NAD+	Strong gross margin, net of pharmacy + shipping	The core recurring earner
Diagnostics / lab panels	Baseline and follow-up metabolic panels	Moderate, often near pass-through	Retention driver and clinical justification
One-time consult / intake	Initial evaluation and plan	Variable	Onboarding, not the recurring engine
Supplements / wellness add-ons	Non-Rx products	Lower margin, easy to sell	Basket size, not the business

The pattern that matters: the recurring compounded subscription is the engine, membership is the flywheel, and everything else is support. A clinic that leans on one-time consults and supplement margin is a retail business wearing a lab coat.

What are the gross margins on compounded subscription revenue?

Gross margins on compounded subscriptions are usually strong at the top line but meaningfully thinner after true costs. The retail price of a compounded therapy sits well above the pharmacy's fill cost, but the honest contribution margin is that spread minus cold-chain shipping, provider time, platform and payment fees, and support. Treat the top-line margin as a starting point, not the take-home.

The costs operators most often forget:

• Pharmacy cost — what the compounding pharmacy charges to fill and dispense.
• Cold-chain shipping — injectables and some peptides need temperature-controlled logistics, which is not cheap and not optional. We cover this in detail in our writing on cold-chain shipping for compounded injectables.
• Provider time — approval, monitoring, and dose management are real clinical labor per patient per month.
• Payment and platform fees — processing plus whatever your fulfillment stack costs.

The operator's job is to know the per-order contribution margin by category, not just the blended number, because the categories differ a lot. For a fuller model of how these numbers stack, see our telehealth clinic unit economics breakdown and the details on compounded Rx pricing and margins.

Why does the multi-category formulary matter so much?

Breadth is the single most important structural decision in a longevity clinic, because it converts regulatory risk from existential to survivable. A single-category clinic lives or dies by one FDA action, one shortage-list change, or one compounding restriction. A clinic running five categories takes a dent from any one of those, not a death blow.

This is the same argument we make in protecting telehealth margins through category diversification: the diversified formulary is a hedge, and the price of the hedge is operational. Running many categories cleanly means running multiple formularies, sometimes multiple pharmacies, and keeping provider approval consistent across all of them. That operational load is exactly where most single-clinic operators break down, and it is why the ability to scale a clinic across multiple categories without rebuilding your stack each time is a real competitive advantage rather than a nice-to-have.

The GLP-1 story is the cautionary tale. Operators who anchored their entire business on compounded semaglutide learned what concentration risk feels like when the FDA shortage status changed. Breadth is the answer, and it has to be designed in from the start, not bolted on after a shock.

How do CAC and LTV work by category?

Acquisition cost and lifetime value both vary sharply by category, so the right way to think about it is per-category unit economics, not a blended average. A metabolic or weight-oriented category tends to have higher intent and higher paid CAC; a hormone or peptide category may acquire more slowly but retain longer. LTV is roughly monthly contribution margin times expected tenure, so retention dominates the math.

A few operator realities on CAC:

1. Paid ads require certification. To run paid acquisition on Google or Meta for a telehealth Rx business, you effectively need LegitScript certification. Budget for it as a cost of the paid channel, not an afterthought.
2. Organic compounds cheaply. Content, referral, and provider reputation lower blended CAC over time — see growing a telehealth brand organically.
3. Category intent differs. The same ad spend buys very different conversion rates across categories, which is why blended CAC hides the truth.

For the benchmark ranges themselves, our telehealth CAC and LTV benchmarks piece goes deeper. The headline for the business model: because the subscription is the earner, a small change in monthly churn moves LTV more than almost any change in acquisition cost. The retention lever is where the value lives, and it is why the subscription refill revenue mechanics deserve as much attention as the funnel.

Where does neolife fit in this model?

neolife is the fulfillment rail that lets a longevity operator run many categories across pharmacies while owning the patient record. It sits on top of the compounding pharmacy a clinic already uses, adds AI-native intake and compliance, and routes each approved order to the right pharmacy. The operator keeps their own storefront and their own patient data as the system of record.

That matters for this specific business model because the multi-category advantage is only real if you can operate it without a rip-and-replace every time you add a category or a pharmacy. neolife automates the order dispatch into pharmacies like Empower, Strive, and Truepill rather than competing with them, and it keeps protected health information off the storefront — which is necessary because Shopify does not sign HIPAA Business Associate Agreements. A licensed provider still approves every order; neolife carries the approval and the routing, not the prescribing. Pricing is flat SaaS plus a per-order buy-down, which keeps it clean of any percentage-of-value or take-rate structure.

If you are building the diversified formulary that makes a longevity clinic durable, the rail is what lets you add the sixth category without rebuilding the first five. If you want to talk through your specific catalog and pharmacy mix, talk to us — we will map your categories, your storefront, and your patient-record architecture before you write a line of integration code.

This post is educational and is not legal, medical, or regulatory advice. Longevity and compounded therapies involve significant compliance and clinical considerations; verify your specific model with qualified counsel and licensed providers before acting.